He focuses on the treatment of prostate, bladder, kidney, and testicular cancer. He also is engaged in research into the role of DNA methylation in prostate and bladder cancer, which looks at how certain genes may be useful molecular markers for disease detection. He received his MD and PhD from the University of Southern California, did his residency at Johns Hopkins, and completed a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center.